Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis

Amanda L. Wright, Sheng Le, Prachi Mehta, Paul Della Gatta, Britt A. Berning, Kelly R. Jacobs, Hossai Gul, Rebecca San Gil, Thomas J. Hedl, Winonah R. Riddell, Owen Watson, Sean S. Keating, Roger S. Chung, Julie D. Atkin, Albert Lee, Bingyang Shi, Catherine A. Blizzard, Marco Morsch, Adam K. Walker
doi: https://doi.org/10.1101/749846
Amanda L. Wright
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheng Le
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prachi Mehta
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Della Gatta
2Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Burwood, VIC, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Britt A. Berning
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
3Neurodegeneration Pathobiology Laboratory, Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly R. Jacobs
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hossai Gul
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca San Gil
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
3Neurodegeneration Pathobiology Laboratory, Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas J. Hedl
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
3Neurodegeneration Pathobiology Laboratory, Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Winonah R. Riddell
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Owen Watson
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean S. Keating
3Neurodegeneration Pathobiology Laboratory, Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger S. Chung
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie D. Atkin
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert Lee
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bingyang Shi
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine A. Blizzard
4Menzies Institute for Medical Research, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Morsch
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam K. Walker
1Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
3Neurodegeneration Pathobiology Laboratory, Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: adam.walker@uq.edu.au
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease most commonly treated with riluzole, a small molecule considered to act at least in part via modulation of glutamatergic neurotransmission. However, riluzole affords only a modest extension of lifespan for people living with ALS and its precise mechanisms of action remain largely unclear. Likewise, the vast majority of ALS cases are characterised by the pathological accumulation of cytoplasmic TDP-43, but the effects of riluzole in an in vivo model of ALS with disease-reminiscent TDP-43 pathology have not been thoroughly studied. We therefore tested the effects of daily riluzole treatment on TDP-43 pathology and disease onset and progression in transgenic mice that inducibly express nuclear localisation sequence (NLS)-deficient human TDP-43 in neurons of the brain and spinal cord (NEFH-tTA/tetO-hTDP-43ΔNLS, ‘rNLS’, mice). We found that treatment of rNLS mice with riluzole beginning from the first day of hTDP-43ΔNLS expression failed to alter disease onset, disease-associated weight loss or performance on multiple motor behavioural tasks over a 6-week period. Riluzole treatment also did not alter soluble or insoluble TDP-43 protein levels or TDP-43 phosphorylation in rNLS mice. By quantifying levels of key proteins involved in glutamatergic signalling, we identified a dramatic loss in GluA3 protein in the rNLS mice after disease onset, however riluzole was unable to ameliorate this disease-associated molecular phenotype. Finally, we assessed the ability of riluzole to affect disease in a long-term post-disease onset study in rNLS mice, and found that riluzole similarly had no effect on progression of late-stage disease or animal survival. Together, our findings demonstrate that the rNLS mouse model recapitulates glutamatergic receptor alterations reminiscent of ALS, but the approved ALS therapeutic riluzole has no effect on disease phenotypes in these animals. These studies suggest that strategies directly targeting disease-relevant pathways, such as accumulation of TDP-43 pathology, may be needed for development of more effective ALS treatments.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 29, 2019.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis
Amanda L. Wright, Sheng Le, Prachi Mehta, Paul Della Gatta, Britt A. Berning, Kelly R. Jacobs, Hossai Gul, Rebecca San Gil, Thomas J. Hedl, Winonah R. Riddell, Owen Watson, Sean S. Keating, Roger S. Chung, Julie D. Atkin, Albert Lee, Bingyang Shi, Catherine A. Blizzard, Marco Morsch, Adam K. Walker
bioRxiv 749846; doi: https://doi.org/10.1101/749846
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis
Amanda L. Wright, Sheng Le, Prachi Mehta, Paul Della Gatta, Britt A. Berning, Kelly R. Jacobs, Hossai Gul, Rebecca San Gil, Thomas J. Hedl, Winonah R. Riddell, Owen Watson, Sean S. Keating, Roger S. Chung, Julie D. Atkin, Albert Lee, Bingyang Shi, Catherine A. Blizzard, Marco Morsch, Adam K. Walker
bioRxiv 749846; doi: https://doi.org/10.1101/749846

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neuroscience
Subject Areas
All Articles
  • Animal Behavior and Cognition (3691)
  • Biochemistry (7800)
  • Bioengineering (5678)
  • Bioinformatics (21295)
  • Biophysics (10582)
  • Cancer Biology (8179)
  • Cell Biology (11945)
  • Clinical Trials (138)
  • Developmental Biology (6764)
  • Ecology (10401)
  • Epidemiology (2065)
  • Evolutionary Biology (13874)
  • Genetics (9709)
  • Genomics (13074)
  • Immunology (8150)
  • Microbiology (20020)
  • Molecular Biology (7859)
  • Neuroscience (43069)
  • Paleontology (321)
  • Pathology (1279)
  • Pharmacology and Toxicology (2260)
  • Physiology (3353)
  • Plant Biology (7232)
  • Scientific Communication and Education (1313)
  • Synthetic Biology (2008)
  • Systems Biology (5539)
  • Zoology (1128)